- Patent Title: 1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders
-
Application No.: US17311974Application Date: 2019-12-12
-
Publication No.: US12247037B2Publication Date: 2025-03-11
- Inventor: Gary Brandt
- Applicant: Neumora Therapeutics, Inc.
- Applicant Address: US MA Watertown
- Assignee: Neumora Therapeutics, Inc.
- Current Assignee: Neumora Therapeutics, Inc.
- Current Assignee Address: US MA Watertown
- Agency: Seed IP Law Group LLP
- International Application: PCT/US2019/066082 WO 20191212
- International Announcement: WO2020/123872 WO 20200618
- Main IPC: C07D519/00
- IPC: C07D519/00 ; A61P25/22
![1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders](/abs-image/US/2025/03/11/US12247037B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to 1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives and related compounds of Formula (I): wherein A, B, G, R1, R1b, RiC, R2 and X are as defined herein. The present compounds are vasopressin receptor antagonists (in particular of the Via receptor) for the treatment of neuro-psychological disorders, such as e.g. autism, anxiety, stress-related disorders, depression, schizophrenia or bipolar disorder. The present description discloses the synthesis of exemplary compounds, as well as pharmacological data thereof (e.g. pages 71 to 246; examples 1 to 49; tables 1 to 5). An exemplary compound is e.g. 8-chloro-1-(2-(5-fluoropyridin-2-yl)-2,6-diazaspiro[3.3]heptan-6-yl)-5-methyl-5,6-dihydro-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine (example 1, compound no. 1).
Public/Granted literature
Information query